Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 7,089 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Clear all

Conditions: Breast Neoplasm
Interventions: Sagopilone (ZK 219477); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 21
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 18 more

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Behavioral Intervention, Quality-of-Life Assessment, Questionnaire Administration; Behavioral · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Quality-of-life Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor
Interventions: CLR457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Yoga Breathing, Attention Control; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer
Interventions: Palbociclib 125mg; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions: Accelerated Partial Breast Irradiation; Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: FFDM Mammography, DBT Mammography; Device
Lead sponsor: Fujifilm Medical Systems USA, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York + 2 more

Conditions: Triple Negative Breast Cancer
Interventions: ENMD-2076; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Indianapolis, Indiana

Conditions: Bone Metastases
Interventions: ExAblate 2100; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 5
States / cities: Duarte, California • San Francisco, California • Stanford, California + 2 more

Conditions: Breast Cancer
Interventions: Docetaxel,doxorubicin, cyclophosphamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 3,299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Advanced Solid Tumor
Interventions: CX-5461; Drug
Lead sponsor: Senhwa Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Breast Cancer
Interventions: bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation; Biological · Drug
Lead sponsor: Premiere Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Breast Cancer
Interventions: Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion, 3D conformal radiation therapy; Drug · Radiation
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Galveston, Texas • Houston, Texas

Conditions: Breast Cancer, Axillary Lymph Node Dissection
Interventions: isosulfan blue dye; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Carcinoma of the Breast
Interventions: Paclitaxel, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 20
States / cities: San Francisco, California • Maywood, Illinois • Indianapolis, Indiana + 13 more

Conditions: Breast Cancer
Interventions: Black Breast Cancer Survivor's Intervention; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Carcinoma, Breast Cancer, Medullary Thyroid Carcinoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Interventions: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride; Drug · Procedure
Lead sponsor: Laura Huppert, MD, BA; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: WashU DIEP Flap Video; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib + an aromatase inhibitor, Palbociclib + Letrozole, Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions: Giredestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Salem, Oregon • Richmond, Virginia

Conditions: Breast Cancer
Interventions: counseling intervention; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 7
States / cities: Canton, Ohio • Chardonr, Ohio • Mentor, Ohio + 4 more

Search by objective public record fields.

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors

Multi-center MRD Registry for Inflammatory Breast Cancer

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Breathwork App for Cancer Survivors

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca

Acquisition of Breast Mammography Images

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Docetaxel in Breast Cancer

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Upper Extremity Lymphatic Mapping for Breast Cancer Patients

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

Collection of Tissue Samples for Study of Multidrug Resistance

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

WashU DIEP Flap Video and Patient Understanding Improvement

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation